Eli Lilly flags unspecified impurities in compounded tirzepatide + B12; compounded GLP-1 liver failure
Key Questions
What issue has Eli Lilly flagged with compounded tirzepatide?
Unspecified impurities in compounded tirzepatide + B12 formulations, with no specific lots or pharmacies named. This raises safety concerns similar to compounded semaglutide variability. Pause new starts until verified.
Why are compounded GLP-1 drugs like tirzepatide riskier than branded?
Compounded versions lack FDA oversight, leading to dosing inconsistencies, impurities, and side effects. Branded options like Mounjaro ensure consistency. Demand Certificates of Analysis (CoAs) for compounded.
What actions should users of compounded tirzepatide take?
Pause new prescriptions, prefer branded tirzepatide or semaglutide, report adverse events, and monitor recalls. Relevant for dysphagia compounding aids. Consult your prescriber.
Eli Lilly's notice on impurities in compounded tirzepatide+B12 (no lots/pharmacies), relevant to dysphagia compounding aids; compounded semaglutide/tirzepatide comparison flags non-FDA variability/dosing/sides; new liver transplant case in healthy wt loss user from unregulated China sources. Pause new starts, demand CoAs, prefer branded, report AEs, watch recalls.